Donor-specific antibodies have become an established biomarker predicting antibody-
mediated rejection. Antibody-mediated rejection is the leading cause of graft loss after …

HLA matching provides numerous benefits in organ transplantation including better graft
function, fewer rejection episodes, longer graft survival, and the possibility of reduced …

De novo donor-specific antibody (dnDSA) develops in 15–25% of renal transplant recipients
within 5 years of transplantation and is associated with 40% lower graft survival at 10 years …

In renal transplantation, polymorphic amino acids on mismatched donor HLA molecules can
lead to the induction of de novo donor‐specific antibodies (DSA), which are associated with …

We conducted a nested case–control study from a cohort of adult kidney transplant
recipients to assess the risk of transplant glomerulopathy (TG) as a function of donor and …

We have assessed whether HLA immunogenicity as defined by differences in donor–
recipient HLA amino‐acid sequence (amino‐acid mismatch score, AMS; and eplet mismatch …

Background Antibody-mediated rejection is a major cause of premature graft loss in kidney
transplantation. Multiple scoring systems are available to assess the HLA mismatch between …

“Epitope matching” became a trending topic in organ transplantation. In fact, discussions on
clinical implementation and utilization of this approach in organ allocation algorithms are …

The need for new approaches to define HLA antibodies, in the context of organ
transplantation, is intensely debated among HLA professionals. In this review, we sought to …

Over the past decade, high HLA epitope mismatch scores have been associated with inferior
transplant outcomes using several tools, of which HLAMatchmaker is most well-known. This …